Latigo Bio
Latigo Biotherapeutics, Inc. ("Latigo Bio") is a clinical-stage biotechnology company headquartered in Thousand Oaks, California, developing novel non-opioid medicines for acute and chronic pain. Its lead candidates LTG-001 and LTG-321 are oral NaV1.8 sodium-channel inhibitors targeting pain at its peripheral source without the addiction risk of opioids; LTG-001 holds FDA Fast Track designation and reported positive Phase 2b results in post-abdominoplasty acute pain, published in the New England Journal of Medicine in July 2026. The company was founded on human-genetics-validated targets and uses in-house AI/ML and structure-based drug design to optimize potency and selectivity. It debuted in 2024 with a $135M Series A and closed a $150M Series B in March 2025, backed by Westlake Village BioPartners, 5AM Ventures, Foresite Capital and Corner Ventures. Latigo is a therapeutics developer, not a software vendor: it publishes no public API, developer portal, SDK or machine-readable specification.
Latigo Bio is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Drug Discovery.
Latigo Bio’s developer surface includes engineering blog and 8 more developer resources.
Kin Score
Terms of Service 1
What its API terms permit and prohibit, quoted from its own page.
Privacy & Data 1
Its role, the data it processes, retention and transfers, quoted from its own privacy page.
Eligibility 1
Who may sign up and where, quoted from its own terms.
Data License 1
How its data and outputs may be reused, quoted from its own terms.
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Commercial 4
Pricing, plans, and the legal terms of use
Company 2
The organization behind the API
Other 2
Properties that don't map to a standard resource type
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.